Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. Co.'s program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). We show 51 historical shares outstanding datapoints in our CAPR shares outstanding history coverage, used to compute CAPR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CAPR market cap history over the course of time is important for investors
interested in comparing CAPR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CAPR versus a peer is one thing; comparing
CAPR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CAPR can fluctuate over the course of history.
With this page we aim to empower investors researching CAPR by allowing them to research the CAPR market cap history. |
Free CAPR Email Alerts:
Video: The Importance of Market Cap
